A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN

被引：0
|
作者：
Alt, J. [1 ]
Bischoff, H. G. [2 ]
Laack, H-E [3 ]
Leistner, R. D. [4 ]
Panse, J. [5 ]
Reinmuth, N. [6 ]
Schulz, C. [7 ]
Grohe, C. [8 ]
机构：
[1] Univ Med Mainz, Mainz, Germany
[2] Univ Hosp Heidelberg, Thoraxklin Heidelberg, Heidelberg, Germany
[3] Hamatol Onkol Hamburg, Hamburg, Germany
[4] Sozialstiftung Bamberg, Med Klin Pneumol Allergol & Schlafmed 4, Bamberg, Germany
[5] RWTH Aachen Univ Hosp, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany
[6] Asklepios Fachkliniken Gauting, Onkol Klin Pneumol, Gauting, Germany
[7] Klinikum Univ Regensburg, Med Klin & Poliklin 2, Regensburg, Germany
[8] Evangel Lungenklin Berlin Krankenhausbetriebs gGm, Klin Pneumol, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
    Chen, L.
    Zhao, Y.
    Wu, H.
    Hu, X.
    Wu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
  • [32] Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
    Goldman, Jonathan W.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Garassino, Marina Chiara
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Ponce, Santiago
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Kazarnowicz, Andrzej
    Losonczy, Gyorgy
    Conev, Nikolay V.
    Armstrong, Jon
    Byrne, Natalie
    Thiyagarajah, Piruntha
    Jiang, Haiyi
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2021, 22 (01): : 51 - 65
  • [33] AMRUBICIN (AMR) VS TOPOTECAN AS SECOND-LINE TREATMENT OF EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (SCLC) SENSITIVE TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY: A RANDOMIZED PHASE 2 TRIAL
    Jotte, R. M.
    Reynolds, C.
    Conkling, P.
    Jungnelius, U.
    Oliver, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 116 - 116
  • [34] A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy
    Ettinger, D. S.
    Jotte, R. M.
    Gupta, V.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer.
    Shi, Jian
    Liu, Jiayin
    Duan, Xiaoyang
    Huang, Guanglei
    Wang, Lixing
    Zhao, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A randomized phase 2 trial of amrubicin compared to topotecan as second-line treatments in extensive disease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Reynolds, C. H.
    Conkling, P.
    Oliver, J. W.
    Allen, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-small cell lung cancer (mNSCLC)
    Hui, Rina
    Munteanu, Mihaela
    Zhao, Yufan
    Luo, Yiwen
    Samkari, Ayman
    Garassino, Marina Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Durvalumab (D) plus /- tremelimumab (T) plus chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
    Cho, Byoung Chul
    Reinmuth, Niels
    Luft, Alexander
    Alatorre-Alexander, Jorge
    Geater, Sarayut Lucien
    Trukhin, Dmytro
    Kim, Sang-We
    Ursol, Grygorii
    Hussein, Maen A.
    Lim, Farah Louise
    Yang, Cheng-Ta
    Araujo, Luiz H.
    Saito, Haruhiro
    Marotti, Miriam
    Barrett, Karen
    Shi, Xiaojin
    Peters, Solange
    Garon, Edward B.
    Mok, Tony S. K.
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES-SCLC): exploratory analysis of patients with long-term clinical benefit in CASPIAN
    Reinmuth, N.
    Paz-Ares, L. G.
    Panse, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 152 - 152
  • [40] Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
    Paz-Ares, Luis
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Ponce, Santiago
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Kazarnowicz, Andrzej
    Losonczy, Gyorgy
    Conev, Nikolay V.
    Armstrong, Jon
    Byrne, Natalie
    Shire, Norah
    Jiang, Haiyi
    Goldman, Jonathan W.
    Batagelj, Emilio
    Casarini, Ignacio
    Pastor, Anea Viviana
    Sena, Susana Noemi
    Zarba, Juan Jose
    Burghuber, Otto
    Hartl, Sylvia
    Hochmair, Maximilian J.
    Lamprecht, Bernd
    Studnicka, Michael
    Schlittler, Luis Alberto
    de Oliveira, Fabricio Augusto Martinelli
    Calabrich, Aknar
    Girotto, Gustavo Colagiovanni
    Dos Reis, Peo
    Gorini, Carlos Fausto Nino
    De Marchi, Peo Rafael Martins
    Baldotto, Clarissa Serodio da Rocha
    Sette, Claudia
    Zukin, Mauro
    Conev, Nikolay V.
    Dudov, Assen
    Ilieva, Rumyana
    Koynov, Krassimir
    Krasteva, Rositsa
    Tonev, Ivan
    LANCET, 2019, 394 (10212): : 1929 - 1939
12345